Exploring Investment Opportunities in Amgen
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 19 hours ago
0mins
Source: Fool
- Market Trend Analysis: In the latest Motley Fool Scoreboard episode, expert analysts delve into Amgen's (AMGN) market trends, offering unique insights into potential investment opportunities that can help investors capitalize on future gains.
- Video Highlights: The episode features a detailed analysis of Amgen's stock performance as of April 22, 2026, aiming to provide viewers with a comprehensive market context and support for investment decisions.
- Investor Education: Through this video, viewers can access the latest information about Amgen and its industry dynamics, enhancing their understanding of the biopharmaceutical sector to make more informed investment choices.
- Future Outlook: Analysts emphasize Amgen's potential in the biopharmaceutical market, particularly in new drug development and market expansion, indicating possible growth opportunities ahead.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy AMGN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on AMGN
Wall Street analysts forecast AMGN stock price to rise
24 Analyst Rating
14 Buy
9 Hold
1 Sell
Moderate Buy
Current: 345.600
Low
280.00
Averages
363.10
High
425.00
Current: 345.600
Low
280.00
Averages
363.10
High
425.00
About AMGN
Amgen Inc. is a biotechnology company. It discovers, develops, manufactures and delivers medicines for the toughest diseases. It focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve people’s lives. It operates in the human therapeutics segment. Its marketed products portfolio includes EPOGEN (epoetin alfa); Aranesp (darbepoetin alfa); Parsabiv (etelcalcetide); Neulasta (pegfilgrastim); KANJINTI (trastuzumab-anns); Otezla; BLINCYTO (blinatumomab); ACTIMMUNE (interferon gamma-1b); Neulasta (pegfilgrastim); Sensipar/Mimpara (cinacalcet); Prolia (denosumab); ENBREL; QUINSAIR (levofloxacin); Repatha (evolocumab) and others. It markets ENBREL, a tumor necrosis factor blocker, in the United States and Canada. It markets Otezla, a small molecule that inhibits phosphodiesterase 4, in many countries around the world. It markets Repatha, a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, in many countries around the world.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Exploring Investment Opportunities in Amgen
- Market Trend Analysis: In the latest Motley Fool Scoreboard episode, expert analysts delve into Amgen's (AMGN) market trends, offering unique insights into potential investment opportunities that can help investors capitalize on future gains.
- Video Highlights: The episode features a detailed analysis of Amgen's stock performance as of April 22, 2026, aiming to provide viewers with a comprehensive market context and support for investment decisions.
- Investor Education: Through this video, viewers can access the latest information about Amgen and its industry dynamics, enhancing their understanding of the biopharmaceutical sector to make more informed investment choices.
- Future Outlook: Analysts emphasize Amgen's potential in the biopharmaceutical market, particularly in new drug development and market expansion, indicating possible growth opportunities ahead.
See More
Analysts Do Not Recommend Amgen Stock
- Investment Opportunity Analysis: In the latest Motley Fool Scoreboard episode, analysts discussed market trends and potential investment opportunities, but Amgen (NASDAQ: AMGN) was not included in the recommended list, indicating a cautious outlook on its future performance.
- Historical Performance Comparison: Although Amgen did not make the recommended top 10 stocks, the Motley Fool Stock Advisor boasts an average return of 968%, significantly outperforming the S&P 500's 211%, suggesting that investors should carefully evaluate stock selections.
- Market Trend Insights: The episode highlighted a company described as an 'Indispensable Monopoly' providing critical technology needed by Nvidia and Intel, indicating a rising focus on related tech companies that could impact Amgen's market performance.
- Value of Investor Community: Motley Fool Stock Advisor not only offers stock recommendations but also fosters a community of individual investors, emphasizing the importance of collective wisdom in investment decisions; despite Amgen not being recommended, investors can still uncover other potential opportunities.
See More
Amgen to Present at Goldman Sachs Healthcare Conference
- Conference Schedule: Amgen will participate in the Goldman Sachs 47th Annual Global Healthcare Conference on June 9, 2026, at 9:20 a.m. ET, featuring presentations by CFO Peter Griffith and EVP of Global Markets and Policy Murdo Gordon, showcasing the company's latest developments.
- Webcast Availability: The conference will be broadcast live over the internet, accessible to media, investors, and the general public, with links and timing details available on Amgen's Investor Relations Events Calendar, ensuring broad audience engagement.
- Replay Feature: The webcast will be archived and available for replay for at least 90 days post-event, allowing investors and the public who missed the live session to access the information, thereby enhancing transparency and information dissemination.
- Company Background: Founded over 45 years ago, Amgen focuses on developing innovative medicines to combat major global diseases, leveraging its leadership in biotechnology to advance drug development in cancer, inflammatory conditions, and rare diseases, demonstrating strong market competitiveness and innovation capabilities.
See More
Quantinuum Debuts on Nasdaq, Raises $1.68 Billion
- Market Debut: Quantinuum began trading on Nasdaq on Thursday with an opening price of $68 per share, representing a 13.3% increase over its upsized IPO price of $60, reflecting strong market interest in the quantum computing sector.
- Capital Raised: The company raised $1.68 billion through its IPO, exceeding its initial price range of $53 to $55, indicating investor confidence in its quantum computing platform and future growth potential.
- Diverse Clientele: Quantinuum serves clients across various sectors including pharmaceuticals, materials science, and finance, with notable customers like JPMorgan Chase and Amgen, showcasing the broad applicability of its technology and solidifying its market position.
- Financial Performance: Despite a 73% year-over-year revenue decline to $5.24 million in Q1 and a net loss of $136.5 million, the CEO emphasized the growing demand for quantum computing resources, suggesting a potential path to profitability in the future.
See More
Quantinuum IPO Raises $1.68 Billion, Valued at $17.6 Billion
- Strong IPO Performance: Quantinuum opened at $68 per share on Nasdaq, raising $1.68 billion and achieving a market cap of approximately $17.6 billion, reflecting robust market interest and confidence in quantum computing.
- Diverse Customer Base: The company serves clients across pharmaceuticals, materials science, and finance, including JPMorgan Chase and Amgen, indicating significant application potential for its quantum computing platform and reinforcing its market position.
- Enhanced Funding Support: The U.S. Department of Commerce announced a $100 million funding commitment to Quantinuum, recognizing its strategic asset status within the quantum ecosystem, which will aid in accelerating technology development and market expansion.
- Financial Challenges: Despite a successful IPO, the company reported a 73% year-over-year revenue decline to $5.24 million in Q1, with a net loss of $136.5 million, highlighting financial pressures and challenges amid rapid expansion.
See More
IMDYLLTRA Approved by EU for Small Cell Lung Cancer Treatment
- Clinical Trial Results: IMDYLLTRA demonstrated a 40% reduction in mortality risk in the DeLLphi-304 Phase 3 study, significantly improving survival rates for small cell lung cancer patients, indicating its potential in treatment.
- Market Approval: The European Commission approved IMDYLLTRA as a monotherapy for small cell lung cancer, addressing a significant market gap for effective treatments after chemotherapy, which is expected to drive the company's growth in oncology.
- Patient Impact: The approval provides a new treatment option for small cell lung cancer patients, particularly those whose disease has progressed after chemotherapy, potentially improving their quality of life and survival duration.
- Safety Analysis: The safety profile of IMDYLLTRA aligns with known treatment characteristics, with 56.7% of patients experiencing cytokine release syndrome; however, the overall safety remains within acceptable limits, demonstrating its clinical applicability.
See More
Exploring Investment Opportunities in Amgen
- Market Trend Analysis: In the latest Motley Fool Scoreboard episode, expert analysts delve into Amgen's (AMGN) market trends, offering unique insights into potential investment opportunities that can help investors capitalize on future gains.
- Video Highlights: The episode features a detailed analysis of Amgen's stock performance as of April 22, 2026, aiming to provide viewers with a comprehensive market context and support for investment decisions.
- Investor Education: Through this video, viewers can access the latest information about Amgen and its industry dynamics, enhancing their understanding of the biopharmaceutical sector to make more informed investment choices.
- Future Outlook: Analysts emphasize Amgen's potential in the biopharmaceutical market, particularly in new drug development and market expansion, indicating possible growth opportunities ahead.
See More
Analysts Do Not Recommend Amgen Stock
- Investment Opportunity Analysis: In the latest Motley Fool Scoreboard episode, analysts discussed market trends and potential investment opportunities, but Amgen (NASDAQ: AMGN) was not included in the recommended list, indicating a cautious outlook on its future performance.
- Historical Performance Comparison: Although Amgen did not make the recommended top 10 stocks, the Motley Fool Stock Advisor boasts an average return of 968%, significantly outperforming the S&P 500's 211%, suggesting that investors should carefully evaluate stock selections.
- Market Trend Insights: The episode highlighted a company described as an 'Indispensable Monopoly' providing critical technology needed by Nvidia and Intel, indicating a rising focus on related tech companies that could impact Amgen's market performance.
- Value of Investor Community: Motley Fool Stock Advisor not only offers stock recommendations but also fosters a community of individual investors, emphasizing the importance of collective wisdom in investment decisions; despite Amgen not being recommended, investors can still uncover other potential opportunities.
See More
Amgen to Present at Goldman Sachs Healthcare Conference
- Conference Schedule: Amgen will participate in the Goldman Sachs 47th Annual Global Healthcare Conference on June 9, 2026, at 9:20 a.m. ET, featuring presentations by CFO Peter Griffith and EVP of Global Markets and Policy Murdo Gordon, showcasing the company's latest developments.
- Webcast Availability: The conference will be broadcast live over the internet, accessible to media, investors, and the general public, with links and timing details available on Amgen's Investor Relations Events Calendar, ensuring broad audience engagement.
- Replay Feature: The webcast will be archived and available for replay for at least 90 days post-event, allowing investors and the public who missed the live session to access the information, thereby enhancing transparency and information dissemination.
- Company Background: Founded over 45 years ago, Amgen focuses on developing innovative medicines to combat major global diseases, leveraging its leadership in biotechnology to advance drug development in cancer, inflammatory conditions, and rare diseases, demonstrating strong market competitiveness and innovation capabilities.
See More
Quantinuum Debuts on Nasdaq, Raises $1.68 Billion
- Market Debut: Quantinuum began trading on Nasdaq on Thursday with an opening price of $68 per share, representing a 13.3% increase over its upsized IPO price of $60, reflecting strong market interest in the quantum computing sector.
- Capital Raised: The company raised $1.68 billion through its IPO, exceeding its initial price range of $53 to $55, indicating investor confidence in its quantum computing platform and future growth potential.
- Diverse Clientele: Quantinuum serves clients across various sectors including pharmaceuticals, materials science, and finance, with notable customers like JPMorgan Chase and Amgen, showcasing the broad applicability of its technology and solidifying its market position.
- Financial Performance: Despite a 73% year-over-year revenue decline to $5.24 million in Q1 and a net loss of $136.5 million, the CEO emphasized the growing demand for quantum computing resources, suggesting a potential path to profitability in the future.
See More
Quantinuum IPO Raises $1.68 Billion, Valued at $17.6 Billion
- Strong IPO Performance: Quantinuum opened at $68 per share on Nasdaq, raising $1.68 billion and achieving a market cap of approximately $17.6 billion, reflecting robust market interest and confidence in quantum computing.
- Diverse Customer Base: The company serves clients across pharmaceuticals, materials science, and finance, including JPMorgan Chase and Amgen, indicating significant application potential for its quantum computing platform and reinforcing its market position.
- Enhanced Funding Support: The U.S. Department of Commerce announced a $100 million funding commitment to Quantinuum, recognizing its strategic asset status within the quantum ecosystem, which will aid in accelerating technology development and market expansion.
- Financial Challenges: Despite a successful IPO, the company reported a 73% year-over-year revenue decline to $5.24 million in Q1, with a net loss of $136.5 million, highlighting financial pressures and challenges amid rapid expansion.
See More
IMDYLLTRA Approved by EU for Small Cell Lung Cancer Treatment
- Clinical Trial Results: IMDYLLTRA demonstrated a 40% reduction in mortality risk in the DeLLphi-304 Phase 3 study, significantly improving survival rates for small cell lung cancer patients, indicating its potential in treatment.
- Market Approval: The European Commission approved IMDYLLTRA as a monotherapy for small cell lung cancer, addressing a significant market gap for effective treatments after chemotherapy, which is expected to drive the company's growth in oncology.
- Patient Impact: The approval provides a new treatment option for small cell lung cancer patients, particularly those whose disease has progressed after chemotherapy, potentially improving their quality of life and survival duration.
- Safety Analysis: The safety profile of IMDYLLTRA aligns with known treatment characteristics, with 56.7% of patients experiencing cytokine release syndrome; however, the overall safety remains within acceptable limits, demonstrating its clinical applicability.
See More
